Plasminogen activators Urokinase

Fig. 3. Overview of puriftcation sequence for the nonrecombinant tissue plasminogen activator (t-PA) which also contains urokinase plasminogen activator (u-PA). Serum-free culture conditional media is from normal human ceU line. The temperature for aU. steps, except for size-exclusion chromatography...

Fig. 4. Fibrinolytic system where SCUPA is single-chain urokinase plasminogen activator rTPA is recombinant tissue plasminogen activator APSAC is acylated plasminogen streptokinase activator complex SK is streptokinase and UK is urokinase.

Mahdi F, Shariat-Madar Z, Todd RF 3rd, Figueroa CD, Schmaier AH Expression and colocahzation of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood 2001 97 2342-2350. 56... 

Figure 51-7. Scheme of sites of action of streptokinase, tissue plasminogen activator (t-PA), urokinase, plasminogen activator inhibitor, and Kj-antiplasmin (the last two proteins exert inhibitory actions). Streptokinase forms a complex with plasminogen, which exhibits proteolytic activity this cleaves some plasminogen to plasmin, initiating fibrinolysis. 

D3. Duffy, M. J., O Grady, P., Devaney, D., O Siorain, L., Fennelly, J. J., and Lijnen, H. R., Urokinase-plasminogen activator, a marker for aggressive breast cancers, preliminary report. Cancer (Philadelphia) 62, 531-533 (1988). 

D7. Duffy, M. J., Urokinase plasminogen activator and malignancy. Fibrinolysis 7, 295-302 (1993). 

J2. Janicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Hoffer, H., and Graeff, H., Urokinase plasminogen activator (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat. 24, 195-208 (1993). 

Y3. Yu, H., and Schultz, R. M., Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res. 50, 7623-7633 (1990). 

Webb, C. P., C. D. Hose, S. Koochekpour, M. Jeffers, M. Oskarsson, E. Sausville, A. Monks, and G. F. Vande Woude. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. 60 342-9.2000. 

Duffy MJ. 2004. The urokinase plasminogen activator system Role in malignancy. Curr Pharm Des 10 39-49. 

Ho YC, Yang SF, Peng CY, Chou MY, Chang YC. 2007. Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator. J Oral Pathol Med 36 588-593. 

Slivova V, Zaloga G, DeMichele SJ, Mukerji P, Huang YS, Siddiqui R, Harvey K, Valachovicova T, Sliva D. 2005. Green tea polyphenols modulate secretion of urokinase plasminogen activator (uPA) and inhibit invasive behavior of breast cancer cells. Nutr Cancer 52 66-73. 

Henderson BR, Tansey WP, Phillips SM, Ramshaw IA, Kefford RF. Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells. Cancer Res 1992 52 2489-2496. 

Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001 276(21) 17976-17984. 

Hoyer-Hansen G, Ronne E, Solberg H, Behrendt N, Ploug M, Lund LR, et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992 267(25)48224-18229. 

Wahlberg K, Hoyer-Hansen G, Casslen B. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res 1998 58(I5) 3294 3298. 

Llinas P, Le Du MH, Gardsvoll H, Dano K, Ploug M, Gilquin B, et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 2005 24(9) 1655-1663. 

---